Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1α, for the treatment of psoriasis
KM Coleman, JE Gudjonsson, M Stecher - JAMA dermatology, 2015 - jamanetwork.com
Methods| Institutional review board approval was obtained before study initiation
(clinicaltrials. gov Identifier: NCT01384630). Patients gave written consent before
enrollment. Patients with a minimum Psoriasis Area and Severity Index (PASI) score of 12
and an affected body surface area of 5% were eligible to be enrolled in this open label,
single-arm trial. Eight patients with a mean (SD) baseline PASI score of 13.8 (1.3) were
enrolled; 5 patients had moderate to severe disease and 3 had moderate disease, as …
(clinicaltrials. gov Identifier: NCT01384630). Patients gave written consent before
enrollment. Patients with a minimum Psoriasis Area and Severity Index (PASI) score of 12
and an affected body surface area of 5% were eligible to be enrolled in this open label,
single-arm trial. Eight patients with a mean (SD) baseline PASI score of 13.8 (1.3) were
enrolled; 5 patients had moderate to severe disease and 3 had moderate disease, as …